Milestone Pharmaceuticals INC. (MIST) — SEC Filings

Overview

Milestone Pharmaceuticals INC. (MIST) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 15, 2025: Milestone Pharmaceuticals Inc. filed an 8-K on December 15, 2025, reporting events that occurred on December 12, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Quebec and its principal exe

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 2 bearish, 38 neutral. The dominant filing sentiment for Milestone Pharmaceuticals INC. is neutral.

Filing Type Overview

Milestone Pharmaceuticals INC. (MIST) has filed 23 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 6 SC 13G/A, 1 SC 13D/A, 1 10-K/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (40)

• Milestone Pharmaceuticals Files 8-K — 8-K · Dec 15, 2025 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on December 15, 2025, reporting events that occurred on December 12, 2025. The filing includes information related t
• Milestone Pharma's Net Loss Widens Amid Increased Commercial Spend — 10-Q · Nov 12, 2025 Risk: high
  Milestone Pharmaceuticals Inc. reported a net loss of $11.922 million for the three months ended September 30, 2025, an increase from a net loss of $9.439 milli
• Milestone Pharmaceuticals Files 8-K on Financials — 8-K · Aug 12, 2025 Risk: low
  On August 12, 2025, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditio
• Milestone Pharma Continues Burn, Eyes Etripamil Progress — 10-Q · Aug 12, 2025 Risk: high
  Milestone Pharmaceuticals Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net l
• Milestone Pharmaceuticals Inc. Files 8-K for Material Agreement — 8-K · Jul 14, 2025 Risk: medium
  On July 11, 2025, Milestone Pharmaceuticals Inc. entered into a Material Definitive Agreement. The company, headquartered in Montreal, Quebec, filed an 8-K repo
• Milestone Pharmaceuticals Inc. Files 8-K for Material Agreement — 8-K · Jul 11, 2025 Risk: medium
  On July 10, 2025, Milestone Pharmaceuticals Inc. entered into a material definitive agreement. The company, headquartered in Montreal, Quebec, filed an 8-K repo
• Milestone Pharmaceuticals Files 8-K — 8-K · Jun 16, 2025 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on June 16, 2025, reporting other events and financial statements. The company, incorporated in Quebec with its prin
• Milestone Pharmaceuticals Inc. Files 8-K: Board & Compensation Changes — 8-K · Jun 12, 2025 Risk: medium
  Milestone Pharmaceuticals Inc. announced on June 10, 2025, a change in its board of directors and executive compensation arrangements. The filing also covers th
• Milestone Pharmaceuticals Files 8-K on Financials — 8-K · May 14, 2025 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Milestone Pharma Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
  Milestone Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including common stock and additio
• Milestone Pharma Files Proxy Statement for June Meeting — DEF 14A · Apr 30, 2025 Risk: low
  Milestone Pharmaceuticals Inc. filed its definitive proxy statement (DEF 14A) on April 30, 2025, for its annual meeting on June 10, 2025. The filing concerns th
• Milestone Pharmaceuticals Files 8-K — 8-K · Mar 28, 2025 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on March 28, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain spe
• Milestone Pharma Files 8-K on Shareholder Nominations — 8-K · Mar 19, 2025 Risk: medium
  Milestone Pharmaceuticals Inc. filed an 8-K on March 19, 2025, reporting a shareholder nomination event as of March 18, 2025. The filing details the company's i
• Milestone Pharmaceuticals Files 8-K: Material Agreement — 8-K · Mar 18, 2025 Risk: medium
  On March 18, 2025, Milestone Pharmaceuticals Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and finan
• Milestone Pharmaceuticals Files 8-K on Financials — 8-K · Mar 13, 2025 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on March 13, 2025, reporting on its results of operations and financial condition. The filing details the company's
• Milestone Pharmaceuticals Files 2024 10-K — 10-K · Mar 13, 2025 Risk: medium
  Milestone Pharmaceuticals Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported total assets of $53.35 million and total liabil
• Milestone Pharmaceuticals Files 8-K Report — 8-K · Feb 25, 2025 Risk: low
  On February 25, 2025, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulati
• Milestone Pharmaceuticals Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing includes financial
• Milestone Pharma Q3 2024 10-Q Filed — 10-Q · Nov 12, 2024 Risk: low
  Milestone Pharmaceuticals Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the
• SC 13G/A Filing — SC 13G/A · Oct 29, 2024
• Milestone Pharmaceuticals Reports Director/Officer Changes & Shareholder Votes — 8-K · Sep 4, 2024 Risk: medium
  Milestone Pharmaceuticals Inc. filed an 8-K on September 4, 2024, reporting on events that occurred on August 28, 2024. The filing includes information regardin
• Milestone Pharmaceuticals Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  On August 8, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as we
• Milestone Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Milestone Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business o
• Alta Fundamental Advisers Amends Stake in Milestone Pharma — SC 13D/A · Jul 16, 2024 Risk: medium
  Alta Fundamental Advisers LLC, through its filing on July 16, 2024, has amended its Schedule 13D regarding Milestone Pharmaceuticals Inc. The filing indicates a
• Milestone Pharmaceuticals Announces Material Agreement and Executive Changes — 8-K · Jul 15, 2024 Risk: medium
  Milestone Pharmaceuticals Inc. announced on July 14, 2024, that it entered into a material definitive agreement. The company also reported the departure of dire
• Milestone Pharmaceuticals Files 8-K — 8-K · May 29, 2024 Risk: low
  On May 29, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no speci
• Milestone Pharmaceuticals Files 8-K Report — 8-K · May 13, 2024 Risk: low
  On May 13, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Quebec, operate
• Milestone Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  Milestone Pharmaceuticals Inc. (MIST) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Milestone Pharmaceuticals Inc. filed a 10-Q report for the p
• Milestone Pharmaceuticals Inc. Files 10-K/A Amendment for Fiscal Year Ended Dec 31, 2023 — 10-K/A · Apr 29, 2024 Risk: low
  Milestone Pharmaceuticals Inc. (MIST) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Milestone Pharmaceuticals Inc. filed an amended 10-
• Milestone Pharmaceuticals Files 8-K — 8-K · Apr 8, 2024 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on April 8, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain spec
• Milestone Pharmaceuticals Files 8-K — 8-K · Mar 28, 2024 Risk: low
  On March 28, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," ind
• Milestone Pharmaceuticals Files 8-K on Financials — 8-K · Mar 21, 2024 Risk: low
  Milestone Pharmaceuticals Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing includes financial sta
• Milestone Pharmaceuticals Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk: medium
  Milestone Pharmaceuticals Inc. (MIST) filed a Annual Report (10-K) with the SEC on March 21, 2024. Milestone Pharmaceuticals Inc. filed its 10-K report for the
• Milestone Pharmaceuticals Inc. Files 8-K — 8-K · Mar 4, 2024 Risk: medium
  On February 28, 2024, Milestone Pharmaceuticals Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing.
• Milestone Pharma Files 8-K on Feb 26 for 'Other Event' — 8-K · Feb 26, 2024 Risk: medium
  Milestone Pharmaceuticals Inc. filed an 8-K on February 26, 2024, reporting an 'Other Event' and 'Financial Statements and Exhibits'. The filing indicates a cur
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Goldman Sachs Amends Milestone Pharma Stake (SC 13G/A) — SC 13G/A · Feb 9, 2024 Risk: low
  Goldman Sachs Group Inc. filed an amended Schedule 13G/A on February 9, 2024, indicating a change in their beneficial ownership of Milestone Pharmaceuticals Inc
• Millennium Sub-Fund Updates Milestone Pharma Stake — SC 13G/A · Jan 29, 2024
  Integrated Core Strategies (US) LLC, a subsidiary of Millennium Management LLC, filed an amended Schedule 13G/A on January 29, 2024, indicating their ownership
• BlackRock Amends Milestone Pharma Stake, Signals Continued Passive Holding — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Milestone Pharmaceuticals Inc. common stock as of December 31, 2023. T

Related Companies

MMP

Frequently Asked Questions